Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Xencor and Adlai Nortye add new oncology data as ESMO roundup widensOct 28Clinical readoutAdlai Nortye Group Ltd.Eikon TherapeuticsUpdated
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819